16 febrero 2018
PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2 .
Feb. 16, 2018
The antibody conjugates MI130004 is the result of combining trastuzumab with the molecule of marine origin belonging to PharmaMar, PM050489.
The prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), has published the results of this antibody conjugate .(
This new molecule causes in HER expressed breast, ovarian and gastric cancers, a longer lasting response and also inhibiting tumor growth increasing the progression free survival in comparison with trastuzumab.
Entrada más reciente